GLP-1 receptor agonists are widely used for type 2 diabetes and weight loss. Their growing use has increased the likelihood that dermatologists will encounter related skin concerns.
A recent analysis of the FDA Adverse Event Reporting System examined reported skin side effects of GLP-1s. The study, which was published in the Journal of Drugs in Dermatology, identified a broad range of dermatologic events. The most frequently reported were pruritus, nonspecific rash, injection-site reactions, urticaria, and alopecia. Hair loss was a particularly notable finding, as it is not widely recognized as a potential effect. Reports of hypersensitivity reactions, including urticaria and rare severe reactions, also suggest a possible immune-mediated component, according to one of the study’s authors, who elaborated on the findings in a Next Steps in Derm interview.
Skin side effects of GLP-1s were reported more often among patients using GLP-1s for weight loss, possibly reflecting higher doses, rapid weight changes, or increased reporting. While some variation in reporting existed among individual agents, the data cannot determine true comparative risk.
Because FAERS is a passive reporting system, the findings show associations rather than causation and likely underestimate true incidence. Overall, GLP-1 therapies remain safe and effective, but dermatologic reactions may be underrecognized.
The key takeaway for clinicians is to consider GLP-1 therapy as a potential contributing factor when evaluating new or unexplained skin findings and to counsel patients accordingly as use of these medications continues to expand.
